VolitionRx demonstrates NuQ blood test detects 95% of pancreatic cancers in second preliminary study
Today Topics ,
VolitionRx Limited has announced that the Company’s NuQ® blood test has accurately detected 95% (19 out of 20) of pancreatic…
VolitionRx Limited has announced that the Company’s NuQ® blood test has accurately detected 95% (19 out of 20) of pancreatic…
VolitionRx Limited has announced that the Company's NuQ® blood test has accurately detected 95% (19 out of 20) of pancreatic…
VolitionRx Limited has announced that full results from a completed clinical study of its NuQ® blood-based test for early stage…
VolitionRx Limited (NYSE MKT: VNRX) today announced that full results from a completed clinical study of its NuQ ® blood-based…